Top Factor Driving Synagis Market Growth in 2025: Rising Prevalence Of Chronic Respiratory Conditions Driving The Market Growth

What Are the Projected Growth and Market Size Trends for the Synagis Market?
Recent years have seen an $XX (CAGR) increase in the size of the Synagis market. Projected growth is evident as its value is expected to rise from $XX million in 2024 to $XX million in 2025, with a Compound Annual Growth Rate (CAGR) of $XX%. This upward trend during the historical period is ascribed to factors such as a surge in expenditure on chronic diseases, escalated investment in research and development, a growing disease load, an upswing in hospitalization rates, and a rising occurrence of chronic respiratory conditions.

Over the coming years, the market size for Synagis is projected to reach an CAGR of $XX%. By 2029, it's expected to skyrocket to $XX million, reflecting a Compound Annual Growth Rate (CAGR) of $XX%. This growth surge during the forecast period can be credited to factors such as an uplift in R&D investments, the increasing incidence of RSV, the rising demand for personalized healthcare and telemedicine, the expansion of the elderly population, and the growing pediatric population in developing markets. Notable trends for the forecast period include progress in RSV treatment, the advancement of biosimilars, clinical trial results, treatment breakthroughs, regulatory endorsements, and the launch of combined vaccines.

What Is Driving the Growth Trajectory of the Synagis Market?
The rise in chronic respiratory diseases is set to stimulate the synagis market's expansion. Chronic respiratory diseases are extended illnesses affecting the lungs and airways which result in ongoing breathing issues. Various reasons contribute to the prevalence of chronic respiratory conditions, such as an aging population, personal habits like smoking, genetic and work-related risks, along with environmental pollution. Synagis (palivizumab) serves to prevent serious respiratory syncytial virus (RSV) infections in infants and children at high risk, minimizing complications and flare-ups in individuals with chronic respiratory conditions. For example, a report by Public Health Scotland, a government organization in Scotland, published in December 2023 revealed that the prevalence of asthma diagnosed by doctors escalated from 16% in 2021 to 17% in 2022. Consequently, the escalating occurrence of chronic respiratory ailments is powering the growth of the synagis market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20304&type=smp

Which Leading Companies Are Shaping the Growth of the Synagis Market?
Major companies operating in the synagis market are Swedish Orphan Biovitrum AB

What Are the Major Trends Shaping the Synagis Market?
A central trend in the Synagis market involves securing drug authorization from regulatory entities in order to introduce a much-needed preventative treatment for the respiratory syncytial virus. Drug authorization represents a review and approval process undertaken by regulatory bodies to release a new drug for use and distribution, verifying its safety, efficacy, and quality through clinical study findings. For instance, in September 2023, AstraZeneca Pharma India Ltd., a pharmaceutical firm based in India, received sanction from the Central Drugs Standard Control Organisation (CDSCO) to sell palivizumab, a preventative treatment for the respiratory syncytial virus (RSV). This approval encompasses the palivizumab 100 mg/ml injection, which comes in 50 mg/0.5 ml and 100 mg/ml single-dose vials for intramuscular administration. This drug is recommended for use in infants who were born at 35 weeks of gestation or less, children who need treatment for bronchopulmonary dysplasia (BPD), and those with hemodynamically significant congenital heart disease (CHD). This authorization signifies a remarkable advancement in treating RSV in India, marking it as the country's first available RSV preventative treatment.

What Are the Key Segments of the Synagis Market?
The synagis market covered in this report is segmented -

1) By Clinical Indication: Respiratory Syncytial Virus (RSV) Prophylaxis; Premature Infants With Bronchopulmonary Dysplasia (BPD); Congenital Heart Disease (CHD); Immunocompromised Infants And Children
2) By Formulation: 50 Milligrams (mg)/0.5 Milliliters (mL); 100 Milligrams (mg)/1 Milliliters (mL)
3) By Distribution Channel: Wholesale Distributors; Online Retailers
4) By End-User: Pediatric; Adults

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/synagis-global-market-report

Which Region Dominates the Synagis Market?
North America was the largest region in the synagis market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the synagis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Synagis Global Market Report?

- Market Size Analysis: Analyze the synagis Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the synagis Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the market.
- Market Contribution: Evaluate contributions of different segments to the overall synagis market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the synagis market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20304

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.